Systematic review with meta‐analysis: comparison between therapeutic regimens for paediatric chronic hepatitis C

Abstract

SUMMARY BackgroundTo decide when and how to treat children with chronic hepatitis C is an ongoing debate.

Estimating the price at which hepatitis C treatment with direct-acting antivirals would be cost-saving in Japan

“…While low-cost DAAs have already been introduced in many developing countries such as India, Pakistan and Egypt 18,40,41 , the prices of these treatments remain high for high-income countries such as Japan where generic DAA medicines are not available. While competition has helped to drive down DAA prices in the public sector in many high-income countries such as the United States 42 , Japan could also benefit by negotiating price of DAAs as described by the WHO Progress Report on Access to DAAs 43 .…”

Systematic review: cost‐effectiveness of direct‐acting antivirals for treatment of hepatitis C genotypes 2‐6

“…Fifth, our review did not identify studies evaluating the cost‐effectiveness of DAAs in populations at high risk of HCV such as immigrants, homeless, and people in prisons and jails . Finally, cost‐effectiveness of hepatitis C treatment in children should be evaluated as clinical data becomes available …”

KASL clinical practice guidelines: management of hepatitis C

“…Little data are available in children [ 528 ]. Although in previous studies on HCV-infected children was limited to interferon-α monotherapy due to the potential teratogenic effects of ribavirin, higher SVR rates have recently been reported with the addition of ribavirin to treatment [ 529 - 533 ].…”